Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of Rheumatology Biologics Register

Arthritis Research and Therapy

Volumn 11, Issue 2, 2009, Pages

  Saad, Amr A ^a   Ashcroft, Darren M ^a   Watson, Kath D ^a   Hyrich, Kimme L ^a   Noyce, Peter R ^a   Symmons, Deborah P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BENIGN TUMOR; BLOOD DISEASE; COHORT ANALYSIS; CYST; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJECTION SITE REACTION; KIDNEY DISEASE; LONG TERM CARE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POLYP; PREDICTION; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; REGISTER; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SURVIVAL; THORAX DISEASE; UNITED KINGDOM; URINARY TRACT DISEASE; DRUG ANTAGONISM; MIDDLE AGED; PATIENT COMPLIANCE; STATISTICS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65449189497     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2670     Document Type: Article

References (31)

1. Ritchlin CT Pathogenesis of psoriatic arthritis Curr Opin Rheumatol 2005, 17:406-412. 10.1097/01.bor.0000167752.93543.76 15956836
2. Antoni C Krueger GG de Vlam K Birbara C Beutler A Guzzo C Zhou B Dooley LT Kavanaugh A Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial Ann Rheum Dis 2005, 64:1150-1157. 1755609 15677701 10.1136/ard.2004.032268
3. Antoni CE Kavanaugh A Kirkham B Tutuncu Z Burmester GR Schneider U Furst DE Molitor J Keystone E Gladman D Manger B Wassenberg S Weier R Wallace DJ Weisman MH Kalden JR Smolen J Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Arthritis Rheum 2005, 52:1227-1236. 10.1002/ art.20967 15818699
4. Genovese MC Mease PJ Thomson GT Kivitz AJ Perdok RJ Weinberg MA Medich J Sasso EH Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy J Rheumatol 2007, 34:1040-1050. 17444593
5. Mease PJ Goffe BS Metz J VanderStoep A Finck B Burge DJ Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial Lancet 2000, 356:385-390. 10.1016/S0140-6736(00)02530-7 10972371
6. Mease PJ Kivitz AJ Burch FX Siegel EL Cohen SB Ory P Salonen D Rubenstein J Sharp JT Tsuji W Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression Arthritis Rheum 2004, 50:2264-2272. 10.1002/art.20335 15248226
7. Mease PJ Gladman DD Ritchlin CT Ruderman EM Steinfeld SD Choy EH Sharp JT Ory PA Perdok RJ Weinberg MA Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 2005, 52:3279-3289. 10.1002/art.21306 16200601
8. Saad AA Symmons DP Noyce PR Ashcroft DM Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials J Rheumatol 2008, 35:883-890. 18381787
9. Coates LC Cawkwell LS Ng NW Bennett AN Bryer DJ Fraser AD Emery P Marzo-Ortega H Sustained response to long-term biologics and switching in psoriatic arthritis: Results from real life experience Ann Rheum Dis 2008, 67:717-719. 10.1136/ard.2007.082925 18055476
10. Silman A Symmons D Scott DG Griffiths I British Society for Rheumatology Biologics Register Ann Rheum Dis 2003, 62(Suppl 2):iI28-ii29. 1766752 14532144
11. Kyle S Chandler D Griffiths CE Helliwell P Lewis J McInnes I Oliver S Symmons D McHugh N Guideline for anti-TNF-alpha therapy in psoriatic arthritis Rheumatology (Oxford) 2005, 44:390-397. 10.1093/rheumatology/ keh514 15695305
12. Electronic Medicines Compendium Summary of Product Characteristics http://emc.medicines.org.uk/industry/default.asp
13. National Institute for Health and Clinical Excellence Technology Appraisal Guidance 104 - etanercept and infliximab for the treatment of adults with psoriatic arthritis http://www.nice.org.uk/TA104
14. Prevoo ML van't Hof MA Kuper HH van Leeuwen MA Putte van de LB van Riel PL Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107 7818570
15. Kirwan JR Reeback JS Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis Br J Rheumatol 1986, 25:206-209. 10.1093/rheumatology/25.2.206 3708236
16. Ware JE Snow KK Kosinski M SF-36 Health Survey Manual and Interpretation Guide Boston, MA: Health Institute, New England Medical Center; 1993.
17. Bousquet C Lagier G Lillo-Le LA Le BC Venot A Jaulent MC Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions Drug Saf 2005, 28:19-34. 10.2165/00002018-200528010-00002 15649103
18. Cramer JA Roy A Burrell A Fairchild CJ Fuldeore MJ Ollendorf DA Wong PK Medication compliance and persistence: Terminology and definitions Value Health 2008, 11:44-47. 18237359
19. Cox DR Fit Cox proportional hazards model Stata Survival Analysis and Epidemiological Tables Reference Manual College Station, TX: Stata Press 1 2007:122-156.
20. Carmona L Gomez-Reino JJ Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER Arthritis Res Ther 2006, 8:R72. 1526631 16620398 10.1186/ ar1941
21. Heiberg MS Koldingsnes W Mikkelsen K Rodevand E Kaufmann C Mowinckel P Kvien TK The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study Arthritis Rheum 2008, 59:234-240. 10.1002/art.23333 18240258
22. Hyrich KL Lunt M Watson KD Symmons DP Silman AJ Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 2007, 56:13-20. 10.1002/art.22331 17195186
23. Duclos M Gossec L Ruyssen-Witrand A Salliot C Luc M Guignard S Dougados M Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients J Rheumatol 2006, 33:2433-2438. 17014004
24. Kristensen LE Gulfe A Saxne T Geborek P Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register Ann Rheum Dis 2008, 67:364-369. 10.1136/ard.2007.073544 17644547
25. Gomez-Reino JJ Carmona L Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period Arthritis Res Ther 2006, 8:R29. 1526564 16507128 10.1186/ar1881
26. Heiberg MS Kaufmann C Rodevand E Mikkelsen K Koldingsnes W Mowinckel P Kvien TK The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study Ann Rheum Dis 2007, 66:1038-1042. 10.1136/ard.2006.064808 17213251
27. Fries JF Spitz P Kraines RG Holman HR Measurement of patient outcome in arthritis Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202 7362664
28. Leung YY Tam LS Kun EW Ho KW Li EK Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses J Rheumatol 2008, 35:1613-1621. 18597399
29. Blackmore MG Gladman DD Husted J Long JA Farewell VT Measuring health status in psoriatic arthritis: The Health Assessment Questionnaire and its modification J Rheumatol 1995, 22:886-893. 8587077
30. Husted JA Gladman DD Cook RJ Farewell VT Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis J Rheumatol 1998, 25:2146-2155. 9818657
31. Petri H Urquhart J Channeling bias in the interpretation of drug effects Stat Med 1991, 10:577-581. 10.1002/sim.4780100409 2057656